Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Retroviral vector transduced B7-H3 CAR T cells + Vorinostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Retroviral vector transduced B7-H3 CAR T cells | Retroviral vector transduced B7-H3 CAR T cells are T cells engineered using a retroviral vector to express a chimeric antigen receptor (CAR) that targets B7-H3, which potentially decrease growth of B7-H3-expressing tumor cells (PMID: 31485480). | |||
Vorinostat | Zolinza | SAHA|L-001079038|MSK390 | HDAC Inhibitor 45 | Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|